Synaptogenix, Inc.

Dec 20, 2024

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

Jun 26, 2024

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

May 07, 2024

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

Apr 03, 2024

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Feb 25, 2021

Synaptogenix to Present at Upcoming Scientific Industry Conferences

Feb 12, 2021

Synaptogenix to Participate in the Winter Wonderland - Best Ideas from the Buy-Side Conference

Feb 09, 2021

Synaptogenix Files Application to List on the Nasdaq Stock Market

Dec 15, 2020

Synaptogenix Schedules Business Update Conference Call